NEUNEUREN PHARMACEUTICALS LIMITED

H1 2025 profit after tax A$15m, up from A$8m in H1 2024

Date and time
Announcement type
Financial Results

More from Health Care

RGTCompany Update29 September 2026

Argent BioPharma (ASX: RGT) Licences NLC Antiviral Portfolio

More News